Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial

Autor: Sverre E. Kjeldsen, Gordon T. Mcinnes, Giuseppe Mancia, Tsushung A. Hua, Stevo Julius, Michael A. Weber, Antonio Coca, Xavier Girerd, Kenneth Jamerson, Pierre Larochelle, Thomas Macdonald, Roland E. Schmieder, M. Anthony Schork, Reuven Viskoper, Jiri Widimský, Alberto Zanchetti, null FOR THE VALUE TRIAL INVESTIGATORS
Rok vydání: 2008
Předmět:
Zdroj: Blood Pressure. 17:170-177
ISSN: 1651-1999
0803-7051
Popis: We have previously shown that the angiotensin receptor blocker valsartan is associated with a lower incidence of new-onset type 2 diabetes than that with the calcium-channel antagonist amlodipine in the treatment of hypertensive patients at high cardiovascular risk. We have now investigated the benefits of valsartan vs amlodipine in patients of different categories of diabetogenic risk. Some 9995 patients without diabetes at onset participated in VALUE, with average follow-up of 4.2 years. Predictors of new diabetes were analyzed by stepwise logistic regression. A diabetes risk score for each patient was calculated based on a multivariate model. The risk of developing new diabetes in quartiles of risk for the disease was calculated as an odds ratio (OR) with 95% confidence intervals (CI). New diabetes was reported in 580 (11.5%) patients on valsartan and in 718 (14.5%) patients on amlodipine (p
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje